The study compares two treatment approaches. One group receives a new drug identified as BV100 together with a low dose of polymyxin B, both given through an IV line. The other group receives the older antibiotic colistin combined with a higher dose of ampicillin/sulbactam, also by IV infusion. The purpose of the trial is to determine which combination works better and is safer for patients with this resistant infection. Participants are randomly assigned to one of the two groups, receive the medication for several days, and are then followed for about a month to see how they recover and to monitor any side effects.

During the study, participants will receive either OMN6 or a placebo through an intravenous infusion, which is a method of delivering fluids directly into a vein. The study is designed to observe how the body responds to different doses of the medication over a single day of treatment. Researchers will monitor how the drug is absorbed and used by the body to determine its safety and how it can be best administered.

The purpose of this research is to evaluate how safe and well-tolerated TP-122 is when given through a nebulizer (a device that turns medicine into a fine mist for breathing) every 8 hours for 7 days. The treatment will be given alongside standard medical care to adults who are on breathing machines in intensive care units.

During the study, participants will receive either the new treatment plus standard care or standard care alone. The research team will monitor patients’ health through various medical tests, including blood work, vital signs, and heart measurements. They will also track how well patients recover from their infection and how long they need to stay in intensive care.

The study tests whether giving additional vitamin D3 along with standard treatment can help patients leave the hospital sooner or reduce inflammation in the body. Participants will receive either vitamin D3 solution (DIBASE) or placebo in the form of refined olive oil. The treatment will be given by mouth and can last up to 12 months.

The research focuses on measuring how well patients recover during their hospital stay, including how quickly they can be discharged and whether they need intensive care. The study will also track changes in substances in the blood that show inflammation levels, particularly proteins called IL-6 and C-reactive protein. Patients will be monitored for up to 90 days to assess their recovery and any effects of the treatment.

Participants diagnosed with tuberculosis will receive standard treatment consisting of two medication combinations. The first combination includes isoniazid, pyrazinamide, rifampicin, and ethambutol hydrochloride taken as tablets for two months. This is followed by a second combination of isoniazid and rifampicin tablets for four months. Throughout the treatment period, researchers will collect blood samples to measure various indicators of disease activity.

The study will also use advanced imaging techniques including PET/MRI scans to monitor how the disease responds to treatment. These scans create detailed pictures of the lungs and can show how the infection changes over time. Blood and sputum (mucus coughed up from the lungs) samples will be collected to measure various substances that might indicate how well the treatment is working.

The purpose of the study is to compare the safety and effectiveness of these treatments in preventing infections in critically ill patients who are on a breathing machine. Participants will receive one or more of these treatments, and their health will be monitored for any severe side effects related to the devices, the antibiotic, or infections. The study will last for up to 14 days, during which the occurrence of respiratory infections like pneumonia and tracheobronchitis will be closely observed.

Throughout the study, researchers will also track other health outcomes, such as the duration of intubation, the length of stay in the intensive care unit, and the overall recovery of the patients. The study aims to provide valuable insights into the best ways to prevent infections in patients who require mechanical breathing support.

The purpose of the study is to determine if a shorter, high-dose treatment is as effective as the traditional longer treatment in terms of patient survival over 90 days. The study will involve patients who are in the intensive care unit (ICU) and are expected to stay there for a certain period. During the trial, some patients will receive the short course, high-dose treatment, while others will receive the conventional treatment. The study will monitor various outcomes, including survival rates, the occurrence of new infections, and the overall health and recovery of the patients.

Participants in the study will be closely monitored for any side effects or complications. The trial aims to find out if the shorter treatment can reduce the exposure to antibiotics without compromising the effectiveness of the treatment. This could potentially lead to better management of antibiotic use in critically ill patients, helping to prevent the development of antibiotic resistance and improve patient outcomes.

The trial will compare the treatment combinations of cefepime/nacubactam and aztreonam/nacubactam against the best available therapy currently used for these infections. Cefepime and aztreonam are antibiotics, while nacubactam is a substance that helps these antibiotics work better against resistant bacteria. The study will involve administering these treatments through an intravenous infusion, which means the medication is given directly into a vein.

Participants in the study will receive one of the treatment combinations or the best available therapy for up to 14 days. The goal is to determine which treatment is most effective in achieving overall treatment success across all the infection types mentioned. The study will also monitor the safety of the treatments to ensure they are safe for use in patients. This trial aims to provide valuable information that could lead to better treatment options for these challenging infections.

The purpose of the study is to see if adding inhaled amikacin sulfate for five days can help clear the lung infection more effectively than the usual treatment alone. Participants in the study will receive either the usual treatment or the usual treatment plus inhaled amikacin sulfate. The study will last for a few days, and researchers will check the infection status on the fifth day to see if the bacteria causing the infection have been cleared.

During the study, the researchers will also monitor the participants for any side effects and will measure how well the medications are working in the body. The goal is to find out if the additional treatment with inhaled amikacin sulfate can improve the recovery from the lung infection in patients who are critically ill and receiving ECMO support.

The purpose of the study is to evaluate the overall survival rate of patients receiving these treatments. Participants in the study will be randomly assigned to receive one of the two treatments. The medications will be given through an intravenous infusion, which means they will be administered directly into a vein. The study will last for a period of up to 14 days, during which the health of the participants will be closely monitored by medical professionals. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments.

Throughout the study, participants will undergo regular health assessments to track their progress and any changes in their condition. The main goal is to determine which treatment is more effective in reducing the mortality rate by the 14th day after starting the treatment. The study will also look at the mortality rate on the 28th day and assess the success of the treatments in clearing the infection. This research aims to provide valuable information that could improve the treatment of these serious lung infections in the future.